Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
ALX Oncology Holdings Inc. granted its Chief Executive Officer and director Jason Lettmann a significant stock option award. On January 26, 2026, he received an option to purchase 912,000 shares of common stock at an exercise price of $1.48 per share, expiring January 25, 2036.
The option vests in 48 equal monthly installments beginning February 26, 2026, meaning the award vests gradually over four years as long as service conditions are met. Following this grant, Lettmann beneficially owns 912,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. updated its employee compensation plans by amending its 2025 Inducement Equity Incentive Plan. Effective January 21, 2026, the board of directors reserved an additional 1,300,000 shares of common stock for issuance under this plan, bringing the total shares reserved to 2,800,000. This plan is used to grant stock options, restricted stock, restricted stock units, stock appreciation rights and performance-based awards, primarily to new hires as a material inducement to join the company. The amendment and the original plan were approved by the board without stockholder approval, consistent with Nasdaq listing rules that allow inducement awards for individuals who were not previously employees or non-employee directors, or who are rehired after a bona fide break in service.
ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman. On January 20, 2026, Goodman received a stock option covering 40,400 shares of common stock with an exercise price of $1.32 per share, expiring on January 19, 2036.
The option vests in 12 equal monthly installments beginning on February 20, 2026, meaning the award becomes fully vested over one year. Following this transaction, Goodman beneficially owned 40,400 derivative securities directly in the form of this stock option.
ALX Oncology Holdings Inc. director receives new stock option grant. Director Garland J. Scott was awarded a stock option covering 40,400 shares of ALX Oncology common stock on January 20, 2026. The option has an exercise price of $1.32 per share and was granted at no purchase price for the option itself. Following this award, Scott beneficially owns 40,400 derivative securities directly.
The option vests in 12 equal monthly installments beginning on February 20, 2026, providing gradual ownership over one year, and is scheduled to expire on January 19, 2036 if not exercised.
ALX Oncology Holdings Inc. director Alan B. Sandler reported a new stock option grant for 10,100 shares of common stock. The option has an exercise price of $1.32 per share and was awarded on January 20, 2026. According to the filing, these option shares vest in 12 equal monthly installments beginning on February 20, 2026, spreading vesting over one year. The option expires on January 19, 2036, and Sandler is shown as directly holding 10,100 derivative securities following this transaction, reflecting this newly granted award.
ALX Oncology Holdings Inc. director Daniel J. Curran reported a new stock option grant in a Form 4 filing. On January 20, 2026, he was awarded a stock option (right to buy) covering 16,833 shares of common stock at an exercise price of $1.32 per share. The option vests in 12 equal monthly installments beginning on February 20, 2026, providing steady monthly vesting over one year. The option expires on January 19, 2036, giving a long-term window to exercise. Following this grant, Curran beneficially owns 16,833 derivative securities directly.
ALX Oncology Holdings director Chris H. Takimoto received a grant of stock options on January 20, 2026. The award covers 40,400 stock options with an exercise price of $1.32 per share, giving the right to buy the company’s common stock at that price in the future. The options expire on January 19, 2036, providing a long-term incentive tied to the company’s share performance.
According to the filing, the 40,400 options vest in 12 equal monthly installments beginning on February 20, 2026. After this grant, Takimoto beneficially owns 40,400 derivative securities directly.
ALX Oncology Holdings Inc. director Rekha Hemrajani received a new stock option grant. On January 20, 2026, she was awarded options to purchase 40,400 shares of ALX Oncology common stock at an exercise price of $1.32 per share. These options were granted at no upfront cost and are held directly.
The options are scheduled to vest in 12 equal monthly installments, beginning on February 20, 2026, and will remain exercisable until January 19, 2036, if service and other applicable conditions are met. After this grant, Hemrajani beneficially owns 40,400 stock options for ALX Oncology common shares.
ALX Oncology Holdings Inc. reported an insider stock sale by Shelly Pinto, the company’s SVP, Finance and CAO. On 01/06/2026, Pinto sold 3,925 shares of common stock at a weighted average price of $1.11 per share, in multiple trades between $1.11 and $1.12.
According to the filing, the sale was made to cover the reporting person’s tax obligations related to the vesting of restricted stock units. After this transaction, Pinto beneficially owned 88,273 shares of ALX Oncology common stock, which includes 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
ALX Oncology (ALXO) reported Q3 2025 results highlighted by lower operating expenses and a smaller loss. Operating expenses were $22.5 million versus $32.6 million a year ago, driven by research and development of $17.4 million and general and administrative of $5.1 million. Net loss was $22.1 million, or $0.41 per share, compared with $30.7 million, or $0.58 per share, in Q3 2024.
Liquidity and balance sheet: Cash, cash equivalents and investments totaled $66.5 million as of September 30, 2025. Net cash used in operating activities was $65.2 million for the nine-month period. The company recorded a $3.2 million impairment in 2025 related to a planned sublease of a Palo Alto facility. Term loan balances were $4.3 million current and $5.8 million non-current. Management believes existing capital resources will fund operations for at least twelve months after the statements are issued.
Pipeline update: An exploratory analysis from the ASPEN‑06 gastric/GEJ study identified CD47 overexpression as a predictive biomarker in patients with retained HER2 expression, with reported outcomes including 65.0% ORR vs 26.1%, 25.5 vs 8.4 months median DOR, and improvements in PFS and OS for Evo‑TRP versus TRP.